Dorman (DORM) Q1 2026 Earnings Transcript

Dorman Products reported Q1 net sales of $529 million, up 4%, with adjusted diluted EPS of $1.57 and operating margin of 12.1% pressured by tariff-related FIFO costs. Management reaffirmed full-year 2026 guidance for 7%-9% sales growth, 15%-16% operating margin, and $8.10-$8.50 EPS, expecting margin improvement as tariff headwinds ease. The company also generated $44 million of operating cash flow, $35 million of free cash flow, and deployed a record $51 million on share repurchases.

Analysis

DORM is in a classic transitory-margin reset, but the important second-order signal is that pricing has already been pushed through faster than the cost headwind can be absorbed. That usually means the next leg is not about top-line acceleration, but about operating leverage as tariff-lagged inventory rolls off FIFO and working capital normalizes; the company is effectively setting up a cleaner earnings inflection into the back half rather than paying for growth today.

The market is likely underappreciating how much of the Q1 compression is self-inflicted by timing rather than demand destruction. If POS stays mid-single digit and customer ordering remains aligned with sell-through, then the “lost volume” narrative should fade by mid-year, while margin recapture becomes the dominant driver. That matters because DORM is levering innovation into categories with higher ASP and stickier attach rates, which should improve mix even if unit growth stays merely steady.

The bigger competitive implication is that tariff volatility is favoring scaled, diversified suppliers over smaller import-dependent competitors. DORM can pass through costs, fund inventory, and keep buying back stock; less-capitalized peers likely cannot, which raises the odds of share gains in both Light Duty and Heavy Duty over the next 2-4 quarters. The hidden catalyst is M&A: once tariff rules stabilize, sellers with impaired margins may come to market, and DORM’s balance sheet gives it optionality to buy growth at a time when private-market valuations should be softer.

Contrarian view: consensus may be too focused on whether margins recover to prior peaks, when the more durable story is that the earnings base is being reset higher through mix and capital returns. The risk is not Q2 arithmetic; it is a renewed tariff regime or a macro rollover that cuts vehicle miles traveled and delays repair spend. But absent a sharper industrial slowdown, the stock likely re-rates on the combination of margin normalization, buybacks, and a more active deal pipeline.

Key Decisions for Investors

• Go long DORM on a 3-6 month horizon, using pullbacks after tariff-driven weakness; risk/reward improves if the stock is still pricing peak-margin compression while guidance implies second-half recovery.
• Sell downside via a DORM put spread 2-3 months out to express the view that Q1 was the trough on margins; highest payoff if the market overreacts to near-term EPS noise.
• Pair trade: long DORM / short a smaller auto-aftermarket peer with higher import exposure and weaker balance sheet; thesis is that tariff normalization will widen share gaps over the next 2-4 quarters.
• Use DORM as a capital-return beneficiary rather than a pure growth name; buy with the expectation that buybacks plus margin recovery can drive multiple expansion into year-end.
• Avoid chasing after strong quarter-to-quarter price action in GM/PII based on DORM’s share gains; the cleaner expression is DORM vs. upstream competitors because the real advantage is supply-chain resilience, not end-market beta.